



it thinks

# Get the full picture with Continuous Glucose Monitoring (CGM)




## 1. GET THE MOST OUT OF YOUR SYSTEM

The MiniMed® System^ is designed as an integrated system. Using CGM allows you to get the greatest benefit from all aspects of the system.



## 2. GET MORE INSIGHT

Knowing where your glucose levels are and where they are headed is essential to avoiding lows and maintaining good control. Our CGM technology continuously monitors your glucose levels and alerts you before they go too high or too low.



**98%** 98 percent of hypoglycaemic events were **detected** by the Enlite™ sensor.<sup>1</sup>

**↓** An integrated insulin pump and CGM system **lowers** your HbA1c without increasing your risk of going low.<sup>2</sup>




### 3. GET ADVANCED PROTECTION

Our exclusive SmartGuard™ technology is a breakthrough in diabetes control. The latest advancement of SmartGuard™ mimics some of the functions of a healthy pancreas by automatically stopping insulin delivery when your sensor glucose is predicted to approach a low limit—and resuming delivery when your levels recover.<sup>3</sup>

#### How SmartGuard™ works in the MiniMed® 640G

(for illustration purposes only)



● SmartGuard™ suspends basal insulin delivery because sensor glucose is predicted to be approaching the preset low limit in 30 minutes.

● Basal insulin delivery automatically resumes because sensor glucose is above the preset low limit and trending upwards.

— Without SmartGuard™    — With SmartGuard™    - - - Predicted Trend

*IMPORTANT: You may also manually resume insulin delivery at any time.*



Stopping insulin delivery has been shown **to reduce** the length of low glucose levels, as well as the number of nocturnal hypoglycaemic events.<sup>4</sup>

**For more information and training on how to use CGM, visit the learning modules and CGM product information at [www.medtronic-diabetes.com.au](http://www.medtronic-diabetes.com.au)**



**Web:** [www.medtronic-diabetes.com.au](http://www.medtronic-diabetes.com.au) **Email:** [australia.diabetes@medtronic.com](mailto:australia.diabetes@medtronic.com)

**Facebook:** [www.facebook.com/MedtronicDiabetesAUS](http://www.facebook.com/MedtronicDiabetesAUS) **Twitter:** @DiabetesANZ **YouTube:** Medtronic Diabetes ANZ  
**Address:** Medtronic Australasia Pty Ltd, 97 Waterloo Road, North Ryde NSW 2113 Australia **Mail:** Medtronic Diabetes, PO Box 945, North Ryde, NSW 1670 **Telephone:** 02 9857 9000 **Facsimilie:** 02 9857 9237 **24-hour Toll Free:** 1800 777 808\*

This information is designed to help you learn more about Diabetes therapy. It is intended to provide you with helpful information but is for information purposes only, is not medical advice and should not be used as an alternative to speaking with your doctor. Be sure to discuss questions specific to your health and treatments with a healthcare professional. For more information please speak to your healthcare professional or log on to: [www.medtronic.com.au](http://www.medtronic.com.au)

#### References:

^Components sold separately. Automated insulin delivery is made possible through combining Medtronic insulin pump and continuous glucose monitoring technology.

\*Please note: In contacting the Diabetes Toll Free, personal and health information may be disclosed to an operator located outside Australia.

1. Enlite™ Sensor Performance Report. Data on file. Northridge, CA 2. Compared to multiple daily injections, according to the STAR 3 clinical study: Bergenstal RM, et al. Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes. NEJM. 2010;363:311–320. 11. Battelino T, et al. The use and efficacy of continuous glucose monitoring in type 1 diabetes treated with insulin pump therapy: a randomized controlled trial. Diabetologia. 2012;55:3155–3162. 3. Must be using Guardian™ 2 Link and Enlite™ sensor to enable the SmartGuard™ feature on the MiniMed® 640G insulin pump. A confirmatory fingerstick is still required prior to making adjustments to diabetes therapy. The dynamic suspend feature is based on certain criteria: sensor glucose must be within 3.9 mmol/L above the low limit and predicted to be 1.1 mmol/L or less above the low limit within 30 minutes AND the pump must not be in the refractory period. The dynamic resume feature is based on certain preset criteria: sensor glucose must be at least 1.1 mmol/L above the preset low limit and predicted to be greater than 2.2mmol/L above within 30 minutes AND insulin must have been suspended for at least 30 minutes. 4. Garg S, et al. Reduction in duration of hypoglycemia by automatic suspension of insulin delivery: the in-clinic ASPIRE study. Diab Tech Ther. 2012;14(3):205–209. 6. Agrawal P, et al. Usage and effectiveness of the Low Glucose Suspend feature of the MiniMed® Paradigm™ Veo™ Insulin Pump. Diab Sci Tech. 2011;5:1137–1141

MiniMed and Medtronic CareLink are registered trademarks and SmartGuard and Bolus Wizard are trademarks of Medtronic MiniMed, Inc.

©2014 Medtronic Australasia Pty Ltd. All rights reserved. 1678-012015